The $2.3 Billion Tax Break: How 280E Elimination Reshapes Cannabis Business

For the past decade, legal cannabis businesses have operated under a tax regime that would bankrupt any other industry. Section 280E of the Internal Revenue Code — a provision originally written in 1982 to prevent drug dealers from deducting business expenses — has forced legitimate, state-licensed cannabis companies to pay federal taxes on gross profit rather than net income. The result: effective tax rates of 70% or higher, compared to the standard 21% corporate rate that applies to virtually every other legal business in America.

With the Justice Department's April 2026 order moving state-licensed medical marijuana to Schedule III, the 280E stranglehold is beginning to loosen. The aggregate annual savings could reach $2.3 billion industry-wide. But the relief is neither universal nor simple, and the companies best positioned to benefit are not necessarily the ones investors expect.

What 280E Actually Does

To understand why 280E elimination is transformational, you need to understand how punishing the provision actually is.

Under normal tax law, a business calculates its taxable income by subtracting ordinary and necessary expenses — payroll, rent, utilities, marketing, insurance, interest on loans — from gross revenue. A cannabis company earning $10 million in revenue with $7 million in expenses would, in any other industry, pay taxes on $3 million in net income.

Under 280E, that same company cannot deduct the $7 million in expenses. It pays taxes on a figure much closer to its gross profit — the revenue minus only the direct cost of goods sold. If cost of goods sold is $4 million, the company pays taxes on $6 million rather than $3 million. At the federal rate of 21%, that is $1.26 million in federal tax instead of $630,000 — double the tax burden, before state taxes even enter the picture.

In practice, the effective rates are often higher because the interplay between 280E and state tax codes creates compounding effects. Some cannabis operators have reported effective tax rates exceeding 80%. The result is an industry where profitable companies on paper are cash-strapped in reality, unable to reinvest in operations, service debt, or return capital to investors.

The Schedule III Relief Mechanism

Section 280E applies specifically to businesses "trafficking in controlled substances within the meaning of schedule I and II" of the Controlled Substances Act. When marijuana moves to Schedule III, it falls outside 280E's scope — businesses dealing in Schedule III substances can deduct expenses like any other company.

The DOJ's April 2026 order moved two categories to Schedule III: FDA-approved marijuana products and marijuana sold under qualifying state medical licenses. This means the 280E relief immediately applies to medical cannabis operators in states with licensed programs.

The catch — and it is a significant one — is that adult-use cannabis remains in Schedule I. Companies operating in recreational markets, or in dual-license states where medical and adult-use operations overlap, face a new complexity: they must segregate their medical and recreational activities for tax purposes, deducting expenses only against medical revenue.

Who Benefits Most

The financial impact varies dramatically depending on a company's market mix and operational structure.

Pure medical operators see the clearest benefit. Companies operating exclusively in medical-only states — or those that can cleanly separate their medical operations — can immediately begin deducting all ordinary business expenses against their medical cannabis revenue. For a mid-size operator doing $50 million in medical sales, the tax savings could exceed $5 million annually.

Multi-state operators with significant medical revenue also benefit substantially. Viridian Capital Advisors estimates the twelve largest MSOs would save a combined $700 million or more per year. Curaleaf, Trulieve, and Green Thumb Industries — the three largest by revenue — each stand to save nine-figure sums. For Trulieve in particular, with its dominant position in Florida's medical market, the impact is massive.

Retailers in high-volume medical states see per-store savings that can be transformative. Cannabis retailers in Maryland, for example, would save an average of $805,000 per store annually — enough to turn marginal locations profitable and fund expansion.

Pure adult-use operators see no direct 280E benefit from the current rescheduling. Companies operating exclusively in recreational markets in states like Colorado, Oregon, or Washington remain subject to 280E until adult-use cannabis is also rescheduled — a question that the June 29 DEA hearing may begin to address but that will not be resolved quickly.

The Compliance Cost Offset

The headline savings numbers are real but somewhat overstated, because Schedule III status brings its own regulatory burden. Moving from Schedule I to Schedule III does not mean less regulation — it means different regulation, and in some respects more of it.

Schedule III substances are subject to DEA registration requirements, prescription tracking, manufacturing standards, and reporting obligations that most cannabis businesses have not previously faced. Companies will need to invest in compliance infrastructure: updated seed-to-sale tracking systems, DEA-compliant record-keeping, staff training, and potentially facility modifications to meet Schedule III security requirements.

Bloomberg Tax analysis suggests these compliance costs will meaningfully dent the tax savings, particularly for smaller operators who lack the administrative infrastructure to absorb new regulatory requirements. Large MSOs with existing compliance teams and sophisticated technology platforms are better positioned to manage the transition efficiently.

This dynamic could accelerate industry consolidation. Smaller operators who struggle with compliance costs may find themselves at a structural disadvantage compared to larger companies that can spread those costs across a broader revenue base.

The Accounting Complexity

The transition from 280E to standard tax treatment is not as simple as flipping a switch. Companies face several immediate accounting challenges.

First, the retroactivity question. Can companies amend prior-year returns to claim deductions that were disallowed under 280E? The IRS and Treasury Department are currently developing guidance, and the answer is likely to depend on the specific dates and circumstances of each company's operations. Some operators have been reserving funds in anticipation of retroactive claims — if those claims are allowed, the one-time cash infusion could be substantial.

Second, the allocation problem. Companies with mixed medical and recreational operations must develop defensible methodologies for allocating shared expenses between 280E-subject and non-280E-subject activities. Shared costs like rent, utilities, and administrative staff must be apportioned based on reasonable metrics — square footage, revenue share, employee time allocation — and the IRS will scrutinize these allocations closely.

Third, the state tax implications. Not all states conform to federal tax treatment, and some have their own versions of 280E-like restrictions. Companies need state-by-state analysis of how federal rescheduling interacts with their state tax obligations.

What Investors Should Watch

For cannabis investors, the 280E elimination changes the fundamental valuation framework. Companies that have appeared perpetually unprofitable on an after-tax basis may suddenly show positive earnings. Cash flow projections improve dramatically. Debt service capacity expands.

But the market is already pricing in some of this expectation. Cannabis stock rallies following the April rescheduling order reflected investor anticipation of 280E relief. The question is whether the actual financial results, once they flow through quarterly earnings, match or exceed what the market has priced in.

The companies to watch most closely are those with the highest proportion of medical revenue, the most efficient compliance operations, and the strongest positions in states where medical cannabis is the primary or exclusive market. These are the operators where 280E elimination translates most directly into bottom-line improvement.

The Long Game

Full 280E relief for the entire cannabis industry — including adult-use — remains contingent on broader rescheduling or legislative action. The June 29 DEA hearing will address whether all marijuana should move to Schedule III, which would extend 280E relief universally. Congressional action, such as standalone 280E reform legislation, is another pathway but faces uncertain political dynamics.

In the meantime, the partial relief from the April order is already reshaping business strategy. Companies are re-evaluating their medical versus recreational market mix, reconsidering capital allocation, and revising their financial projections. The $2.3 billion question is no longer whether 280E relief is coming — it is how quickly it arrives for the entire industry and whether businesses can navigate the transition without stumbling over the compliance complexity that comes with it.